Xiamen Amoytop Biotech Co Ltd (688278) — Working Capital to Net Assets Ratio
Xiamen Amoytop Biotech Co Ltd (688278) has a Working Capital to Net Assets ratio of 54.8% as of June 2025. Working capital of CN¥1.51 Billion (current assets of CN¥1.87 Billion minus current liabilities of CN¥359.79 Million) is measured against net assets of CN¥2.76 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See how leveraged is Xiamen Amoytop Biotech Co Ltd's balance sheet to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Xiamen Amoytop Biotech Co Ltd Working Capital to Net Assets (2016–2024)
This chart shows how Xiamen Amoytop Biotech Co Ltd's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2016 to 2024. As of June 2025, the ratio stands at 54.8%, reflecting working capital of CN¥1.51 Billion against net assets of CN¥2.76 Billion CNY. Check tangible net worth ratio of Xiamen Amoytop Biotech Co Ltd to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Xiamen Amoytop Biotech Co Ltd (2016–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Xiamen Amoytop Biotech Co Ltd from 2016 to 2024, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Xiamen Amoytop Biotech Co Ltd market cap and net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 55.1% | CN¥1.41 Billion | CN¥2.55 Billion | CN¥1.83 Billion | CN¥420.63 Million | ▲ +5.2 pp |
| 2023 | 49.9% | CN¥936.53 Million | CN¥1.88 Billion | CN¥1.34 Billion | CN¥403.66 Million | ▲ +1.1 pp |
| 2022 | 48.9% | CN¥687.72 Million | CN¥1.41 Billion | CN¥955.61 Million | CN¥267.89 Million | ▼ -7.7 pp |
| 2021 | 56.6% | CN¥657.19 Million | CN¥1.16 Billion | CN¥834.42 Million | CN¥177.23 Million | ▼ -9.2 pp |
| 2020 | 65.8% | CN¥657.86 Million | CN¥1.00 Billion | CN¥772.80 Million | CN¥114.94 Million | ▲ +13.5 pp |
| 2019 | 52.3% | CN¥294.48 Million | CN¥563.55 Million | CN¥445.20 Million | CN¥150.72 Million | ▲ +3.4 pp |
| 2018 | 48.8% | CN¥243.81 Million | CN¥499.26 Million | CN¥373.85 Million | CN¥130.04 Million | ▲ +12.2 pp |
| 2017 | 36.6% | CN¥176.81 Million | CN¥483.26 Million | CN¥295.38 Million | CN¥118.57 Million | ▲ +1.1 pp |
| 2016 | 35.5% | CN¥169.66 Million | CN¥478.09 Million | CN¥301.80 Million | CN¥132.15 Million | — |